Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects

NCT03687632 is registered in ClinicalTrials.gov with Noveome Biotherapeutics, formerly Stemnion as lead sponsor.

NCT NCT03687632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03687632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open Label Trial of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2019
Completion date
August 25, 2020
Enrollment
13 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

persistent corneal epithelial defect